Teva hit by another PhIII setback on CGRP pain drug fremanezumab, but there’s no pulling back now as rivals race ahead
Teva has already been pushed back to a follow-up shot at the CGRP migraine drug market. Now it’s also lost a Phase III round that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
